BioCentury | Apr 1, 2019
Emerging Company Profile

Arixa: Breaking resistance with oral beta lactamase inhibitors

...decrease avibactam’s activity. At least two companies are developing oral β-lactamase inhibitors. Entasis Therapeutics Inc.’s ETX0282...
BioCentury | Sep 8, 2017
Finance

Antibiotic engine

...stage, and the next stage could see us with proof-of-concept data with ETX2514 and bring ETX0282...
...treat undisclosed Gram-negative infections. Perros would not say when he expects the trials to start. ETX0282...
...oral inhibitor of class A and C LACTB in preclinical development. The company is developing ETX0282...
Items per page:
1 - 2 of 2